Eagle Pharma
FDA 503B outsourcing facility
Birmingham, Alabama
Key Takeaways
- FDA-registered 503B outsourcing facility since 2015
- Sterile compounding from bulk substances: Yes
- Last FDA inspection: February 27, 2025
- 1 FDA drug recall on record (2015)
About this facility
A 503B outsourcing facility is registered with the FDA under the Drug Quality and Security Act and may compound sterile medications in bulk without patient-specific prescriptions, under cGMP manufacturing standards. How federal compounding status works.
FDA registration and inspection record
- First registered with FDA
- June 16, 2015
- Most recent registration
- December 16, 2025
- Compounds sterile drugs from bulk substances
- Yes
- Last FDA inspection
- February 27, 2025
The FDA last inspected Eagle Pharma on February 27, 2025. Investigators issued a Form FDA 483 listing inspectional observations at that visit. The FDA has not yet determined whether further action will be taken.
FDA recall history
Eagle Pharma has 1 FDA drug recall on record in 2015, based on the FDA enforcement database. Breakdown: 1 Class II.
Recall reasons on record include subpotent drug: trace amounts of methylcobalamin in compounded drug.
| Date | Class | Product | Reason |
|---|---|---|---|
| August 2015 | Class II | LIPO B STERILE INJECTION 10 mL ( Methionine 25 mg, Inositol 50 mg, Choline Chloride 50 mg, Pyridoxine Hydrochloride 5 mg, Methylcobalamin 0. | Subpotent Drug: trace amounts of methylcobalamin in compounded drug. |
FDA recall classes signal severity, not intent: Class I means a reasonable probability of serious harm, Class II a temporary or reversible risk, Class III a violation unlikely to cause harm. Sterile compounders routinely recall lots as a precaution. FDA definitions.
What this facility compounds
Eagle Pharma reports compounding 9 distinct active ingredients to the FDA Outsourcing Facility Product Report (most recent reporting periods).
Tracked on PeptideGrids: Semaglutide.
- Betamethasone Acetate; Betamethasone Sodium Phosphate
- Brompheniramine Maleate
- Dexamethasone Acetate Anhydrous
- Ketorolac Tromethamine
- Lidocaine; Tetracaine
- Lidocaine; Tetracaine; Benzocaine
- Methylprednisolone Acetate
- Semaglutide
- Triamcinolone Acetonide
Location
2200 Riverchase Ctr Ste 675, N/A, Hoover, AL 35244-2918
Contact
FDA-registered contact: Haleigh Cawood, 205-682-7999. Source: the facility's FDA outsourcing registration.
License verification
503B outsourcing facilities are also licensed by the state board of pharmacy. Verify the current license status of Eagle Pharma with the Alabama State Board of Pharmacy.
503B facilities in Alabama
Alabama has 2 FDA-registered 503B outsourcing facilities in the PeptideGrids directory. See all 503B facilities in Alabama.
Frequently asked questions
Is Eagle Pharma registered with the FDA?
Yes. Eagle Pharma is a registered 503B outsourcing facility, first registered with the FDA on June 16, 2015 and most recently registered on December 16, 2025.
Has Eagle Pharma been inspected by the FDA?
The FDA last inspected Eagle Pharma on February 27, 2025. A Form FDA 483 was issued.
Has Eagle Pharma had any FDA drug recalls?
Eagle Pharma has 1 FDA drug recall on record (2015) in the FDA enforcement database.
What does Eagle Pharma compound?
Eagle Pharma reports compounding 9 active ingredients to the FDA, including Semaglutide.
Where is Eagle Pharma located?
Eagle Pharma is located in Birmingham, Alabama (2200 Riverchase Ctr Ste 675).
Registration and inspection data verified against the FDA list of registered outsourcing facilities on June 6, 2026. Recall history from the FDA openFDA drug enforcement database, retrieved June 6, 2026.
PeptideGrids is independent and not affiliated with, endorsed by, or sponsored by Eagle Pharma. Listings, registration, inspection, and recall data are reported from public FDA records for informational purposes only. A recall or inspection finding is not an accusation of current wrongdoing. This is not medical or legal advice. To request a correction, see our corrections policy.